Clinical trial · Interventional
Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer
Use of the Epidermal Expansion System to Harvest and Place Suction Blister Epidermal Grafts on Wounds in Patients After Mohs or Excisional Surgery for Skin Cancer
NCT01536444CI-TRIAL-00006318unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This case series will assess the use of suction blister epidermal grafts harvested by a novel device on select patients that have wounds from Mohs or excisional surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm of Skin | Skin Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Momelan Technologies Epidermal Graft Harvesting System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Micrografting
- interventionNames
- Device: Momelan Technologies Epidermal Graft Harvesting System
Primary outcomes (1)
- measure
- Wound healing/scarring
- timeFrame
- 6 weeks
Secondary outcomes (3)
- measure
- Incidence of adverse events
- timeFrame
- 6 weeks
- measure
- Physician global satisfaction
- timeFrame
- 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Adult males and females between 35 and 90 years of age * Status post skin cancer removal on the scalp, ear or leg with a wound that would otherwise be allowed to heal by secondary intention or grafting * Wound considered appropriate by physician to receive epidermal grafting * Willingness to participate in study by evidence of informed consent Exclusion Criteria: * Female patients reported to be breastfeeding, pregnant or planning to become pregnant * Clinical signs of infection * Subjects currently on immunosuppressive medications, chemotherapy or a cytotoxic agent * Participation in another interventional study with potential exposure to an investigational drug or device within the past 30 days or planned study entry within 90 days after study entrance.
References
Publications (0)
Data not yet available
No reference posted for this study.